Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with 89Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts

Oncotarget

Volumn 6, Issue 39, 2015, Pages 42081-42090

  ter Weele, Eva J ^a   van Scheltinga, Anton G T Terwisscha ^a   Kosterink, Jos G W ^a,b   Pot, Linda ^a   Vedelaar, Silke R ^a   Lamberts, Laetitia E ^a   Williams, Simon P ^c   Lub de Hooge, Marjolijn N ^a   de Vries, Elisabeth G E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c GENENTECH INC   (United States)

Author keywords

IRDye 800CW; Mesothelin; Pancreatic cancer; PET imaging; Zirconium 89

Indexed keywords

INDIUM IMMUNOGLOBULIN G IN 111; MESOTHELIN; RADIOPHARMACEUTICAL AGENT; TRACER; UNCLASSIFIED DRUG; ZIRCONIUM MESOTHELIN ANTIBODY CONJUGATE ZR 89; ANTIBODY CONJUGATE; BENZENESULFONIC ACID DERIVATIVE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; INDOLE DERIVATIVE; IRDYE 800CW; MONOCLONAL ANTIBODY; RADIOISOTOPE; ZIRCONIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONJUGATION; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG UPTAKE; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; TISSUE DISTRIBUTION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CHEMISTRY; CYTOPLASM; DIAGNOSTIC IMAGING; IMMUNOLOGY; METABOLISM; NUDE MOUSE; PANCREAS TUMOR; PATHOLOGY; PROCEDURES; TIME FACTOR; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; BENZENESULFONATES; CELL LINE, TUMOR; CYTOPLASM; GPI-LINKED PROTEINS; HUMANS; IMMUNOCONJUGATES; IMMUNOHISTOCHEMISTRY; INDOLES; MALE; MICE, INBRED BALB C; MICE, NUDE; MICROSCOPY, FLUORESCENCE; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; TIME FACTORS; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS; ZIRCONIUM;

EID: 84951837092     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5877     Document Type: Article

References (26)

1. Dibble EH, Karantanis D, Mercier G, Peller PJ, Kachnic LA, Subramaniam RM. PET/CT of cancer patients: part 1, pancreatic neoplasms. AJR Am J Roentgenol. 2012; 199:952-967.
2. Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. Clin Cancer Res. 2012; 18:4266-4276.
3. Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer. 2008; 44:46-53.
4. Frierson HF Jr, Moskaluk CA, Powell SM, Zhang H, Cerilli LA, Stoler MH, Cathro H, Hampton GM. Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum Pathol. 2003; 34:605-609.
5. Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz RE, Murugesan SR, Leach SD, Jaffee E, Yeo CJ, Cameron JL, Kern SE, Hruban RH. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 2001; 7:3862-3868.
6. Kumar-Sinha C, Wei I, Simeone DM. Emerging frontiers in pancreatic cancer research: elaboration of key genes, cells and the extracellular milieu. Curr Opin Gastroenterol. 2012; 28:516-522.
7. Chang K, Pastan I, Willingham MC. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer. 1992; 50:373-381.
8. Hassan R, Miller AC, Sharon E, Thomas A, Reynolds JC, Ling A, Kreitman RJ, Miettinen MM, Steinberg SM, Fowler DH, Pastan I. Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci Transl Med. 2013; 5:208ra147.
9. Hassan R, Sharon E, Thomas A, Zhang J, Ling A, Miettinen M, Kreitman RJ, Steinberg SM, Hollevoet K, Pastan I. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for frontline therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. Cancer. 2014; 120:3311-3319.
10. 89Zr-labeled transforming growth factor-β antibody fresolimumab in tumor models. J Nucl Med. 2011; 52:2001-2008.
11. 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med. 2009; 50:974-981.
12. 64Cu-labelled Fab for detecting ERC/mesothelin in a mesothelioma mouse model. Nucl Med Commun. 2010; 31:380-388.
13. 89Zr-labelled monoclonal antibodies for immunoPET. Nucl Med Biol. 2010; 37:289-297.
14. 89Zr in mice. Nucl Med Biol. 2011; 38:675-681.
15. Ogasawara A, Tinianow JN, Vanderbilt AN, Gill HS, Yee S, Flores JE, Williams SP, Ashkenazi A, Marik J. ImmunoPET imaging of phosphatidylserine in pro-apoptotic therapy treated tumor models. Nucl Med Biol. 2013; 40:15-22.
16. 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patient with metastatic breast cancer. J Clin Pharm Ther. 2010; 87:586-592.
17. 89Zr immuno-PET. J Nucl Med. 2014; 55:2045-2049.
18. 89Zr-trastuzumab and 18F-FDG to individualize treatment with trastuzumab emtansine (T-DM1) in metastatic HER2-positive breast cancer (mBC). J Clin Oncol. 2014; 32:5s. (suppl; abstr 11001).
19. Lamberts LE, de Groot DJ, Bense RD, de Vries EG, Fehrmann RS. Functional genomic mRNA Profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types. Oncotarget. 2015; 6:28164-28172.
20. 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging. Oncotarget. 2015; 6:4496-4504.
21. Weekes CD, Lamberts LE, Borad MJ, Voortman J, McWilliams RR, Robinson Diamond J, De Vries EGE, Verheul HMW, Hanyoung Lieu C, Yue H, Wang Y, Scales S, Samineni D, et al. A phase I study of DMOT4039A, an antibody-drug conjugate (ADC) targeting mesothelin (MSLN), in patients (pts) with unresectable pancreatic (PC) or platinum-resistant ovarian cancer (OC). J Clin Oncol. 2014; 32:15s. (suppl; abstr 2529).
22. Verel I, Visser GW, Boerman OC, van Eerd JE, Finn R, Boellaard R, Vosjan MJ, Stigter-van Walsum M, Snow GB, van Dongen GA. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. Cancer Biother Radiopharm. 2003; 18:655-661.
23. Ruegg CL, Anderson-Berg WT, Brechbiel MW, Mirzadeh S, Gansow OA, Strand M. Improved in vivo stability and tumor targeting of bismuth-labelled antibody. Cancer Res. 1990; 50:4221-4226.
24. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med. 2010; 51:761-767.
25. Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging. 2003; 2:131-137.
26. Terwisscha van Scheltinga AG, van Dam GM, Nagengast WB, Ntziachristos V, Hollema H, Herek JL, Schröder CP, Kosterink JG, Lub-de Hooge MN, de Vries EG. Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. J Nucl Med. 2011; 52:1778-1785.